You are here: Industry Insights > Pancreatic cancer

News List

US FDA grants ODD for OBI Pharma’s OBI-888 to treat pancreatic cancer pharmaceutical-technology
November 29, 2018
Taiwan, Chinaese biopharma company OBI Pharma has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for OBI-888 to treat pancreatic cancer patients......
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer pharmafocusasia
November 26, 2018
OBI Pharma, Inc., a Taiwan, China biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for....
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer pharmafocusasia
November 26, 2018
OBI Pharma, Inc., a Taiwan, China biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for....
NuMedii Announces Research Collaboration With Leading Academic Research Institution pharmafocusasia
November 05, 2018
NuMedii, Inc., today announced the formation of a research collaboration with Johns Hopkins School of Medicine with the goal of discovering...
Novocure speeds up trial of drug-device combo in pancreatic cancer fiercebiotech
August 16, 2018
Novocure has teamed up with a cancer physician network to accelerate patient recruitment in its pivotal pancreatic cancer trial, which pairs a tumor-killing device with chemotherapy.
Pancreatic cancer survival much lower than thought, research finds pharmatimes
June 21, 2018
Pancreatic Cancer UK is calling for greater investment in research funding for pancreatic cancer as new data reveals that just three percent of patients with the most common form will survive beyond five years.
Sun Biopharma Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and N biospace
January 30, 2018
Sun BioPharma, Inc. (OTCQB: SNBP) today announced the start of a first-line dose escalation study of gemcitabine and paclitaxel in combination with SBP-101
BioLineRx Announces Partial Monotherapy Results From Phase IIa COMBAT Study in Pancreatic Cancer biospace
January 18, 2018
Partial results of the monotherapy portion of Phase 2a COMBAT study of BL-8040 showed that BL-8040 increased the tumor invasion of tumor and immune infiltrating T cells into patients with metastatic pancreatic cancer.
FDA approves pan-tumour genomic profiling assay biospectrumasia
December 11, 2017
FoundationOne CDx allows to assess genomic alterations in 324 genes known to drive cancer growth
Four genes linked to pancreatic cancer identified biospectrumasia
November 07, 2017
The team found that patients who had three or four of the altered genes had worse disease-free survival - the time between surgery and when the cancer returns - and overall survival - from surgery to death - compared to patients with a single or two alter

Previous page 1 2 3 4 5 6 Next page